An intranasal adjuvanted, recombinant influenza A/H5 vaccine primes against diverse H5N1 clades: a phase I trial

Journal:

Nature Communications

Published:

2025-11-06

DOI:

10.1038/s41467-025-64686-3

Affiliations:

5

Authors:

34

Go to article

Institutions	Authors	Share
Center for Vaccine Development and Global Health (CVD), UMB, United States of America (USA)	21.000000 21.000000 21.000000	0.62
Center for Biologics Evaluation and Research (CBER), USFDA, United States of America (USA)	6.000000	0.18
BlueWillow Biologics, United States of America (USA)	5.000000	0.15
University of Maryland, Baltimore (UMB), United States of America (USA)	2.000000	0.06

Interested in Clinical Sciences?